Beursonline.nl

[verwijderd] 16 mei 2009 20:18

3

in.us.biz.yahoo.com/e/090515/tpim.ob1...

Tapimmune

Crucell Agreement
Pursuant to the Research License and Option Agreement Crucell granted us a non-exclusive, worldwide license for Crucell's adenovirus technology and an option for a non-exclusive, worldwide commercial license to manufacture, use, offer for sale, sell and import products using the licensed technology in the therapy of human subjects by administering a modified and proprietary adeno virus vector (used to package our TAP gene technology and deliver it to the target cancer cell in the patient) including, but not limited to, therapeutic gene sequence(s). Total obligations under this agreement were �450,000. In May 2006 we negotiated a reinstatement of the original Research and License Option Agreement with Crucell and paid Crucell �123,590 ($151,521) in connection with the reinstatement. Under the revised terms of the agreement, we were to pay Crucell twelve monthly payments of �10,300 starting May 2006 (paid to October 31, 2006) and a �75,000 annual license fee (adjusted for CPI) in order to keep the reinstated agreement in good standing. In January, 2008 the Company paid �27,316 ($40,000) towards the outstanding balance and at March 31, 2009 �172,801 ($229,927) has been included in research agreement obligations for the Crucell agreement. Over the last few months we have had discussions resulting in an informal commitment to hold our license in a dormant state until we are able to meet some of the payment requirements and are funded to continue with our development program.

josti5 17 mei 2009 08:40

0

Tnx gocrucellgo; even opmerkelijk als interessant, deze openheid!
Geeft ook inzicht in het huidige reilen en zeilen van Crucell zelf, met betrekking tot het licentiegebeuren.

flosz 18 mei 2009 20:44

0

11 May 2009, 0204 hrs IST
What are viruses? Viruses are neither living organisms nor non-living things because they show properties of both. Like other living organisms they can reproduce, but only when they are inside a living cell. Unlike all other living beings, viruses cannot convert energy and grow. They have been called biomolecules. First discovered in 1894, they were actually seen only after 1940s when advanced magnification...

www.youtube.com/watch?v=7O9JPyY44VA

flosz 27 mei 2009 10:49

0

05:33 GMT, May 27, 2009 CONTRACTS

DEFENSE LOGISTICS AGENCY
MedImmune Vaccines, Inc., Gaithersburg, Md., is being awarded a maximum $32,293,397 firm fixed price, sole source contract for influenza vaccine. Other location of performance is in Pennsylvania. Using services are Army, Navy, Air Force, Marine Corps and federal civilian agencies. Contract funds will not expire at the end of the current fiscal year. There was one response to the original proposed solicitation. The date of performance completion is Jun. 30, 2010. The contracting activity is the Defense Supply Center Philadelphia (DSCP), Philadelphia, Pa. (SPM2DP-09-D-0005).

Sanofi Pasteur, Swiftwater, Pa., is being awarded a maximum $12,368,596 firm fixed price contract for influenza vaccine. There are no other locations of performance. Using services are Army, Navy, Air Force, Marine Corps and federal civilian agencies. Contract funds will not expire at the end of the current fiscal year. There were eight proposals originally solicited with one response. The date of performance completion is May 26, 2010. The contracting activity is the Defense Supply Center Philadelphia, Philadelphia, Pa. (SPM2DP-09-D-0007).
www.defpro.com/news/details/7656/
******************
Winnipeg researcher charged with smuggling Ebola material into U.S.
Last Updated: Wednesday, May 13, 2009 | 6:35 PM ET Comments131Recommend114
CBC News
A former researcher at the National Microbiology Lab in Winnipeg is facing charges in the United States after allegedly trying to smuggle genetic material from the Ebola virus across the Manitoba-North Dakota border.
U.S. authorities allege Konan Michel Yao had 22 vials of the substance in the trunk of his car when he tried to cross the border on May 5. He is charged with smuggling merchandise, which carries a maximum penalty of 20 years in prison and a fine of $250,000 US.
U.S. customs officers allegedly found the vials wrapped in aluminum foil inside a glove and packaged in a plastic bag, along with electrical wires.
In his affidavit, the 42-year-old researcher said he was hired by the Public Health Agency of Canada to work as a PhD fellow at the Winnipeg facility. Yao told officers he was working on a vaccine for the Ebola virus and HIV.
On Jan. 21, his last day at the lab, he said he stole 22 vials, which he described as research vectors, according to the affidavit.
Yao told officers he was taking the vials to his new job with the National Institutes of Health at the Biodefense Research Laboratory in Bethesda, Md., because he didn't want to start from scratch in his research.
Dr. Frank Plummer, the scientific director of the Winnipeg lab, said the genetic material taken was not the full Ebola virus and does not pose a risk to the public.
Plummer said theft has never happened at the lab before. Researchers are reminded they cannot take any lab property without permission, and they sign documents asserting that they know the rules, he said.
The lab is now reviewing its biosecurity protocol.
No public health risk, Canadian health agency says
Lynn Jordheim, the U.S. attorney prosecuting the case, said Yao was not carrying the active viruses. Still, Jordheim said, the allegations against Yao are serious.
"You take it seriously when something like this happens, but this is not the scenario you fear where somebody would be bringing a biological agent across," Jordheim said.
A spokesman with the U.S. Federal Bureau of Investigation's Minnesota office told CBC News on Wednesday that the agency was initially called in to investigate and monitor a terrorist threat, but the threat was assessed and ruled out.
The FBI said U.S. Immigration and Customs Enforcement will be handling the investigation.
The Public Health Agency of Canada said there was never a public health risk, and insisted Yao did not have access to the highest-level pathogens and only worked with non-infectious material.
A spokesperson for the agency confirmed that the accused was a researcher who hadn't worked at the National Microbiology Lab since January.
Yao was born in the Ivory Coast. He studied at Laval University in Quebec and was briefly affiliated with the plant sciences department at the University of Manitoba.
A former supervisor described him as "a normal researcher."
www.cbc.ca/canada/story/2009/05/13/bo...
www.ncbi.nlm.nih.gov/pubmed/19390586
www.plosone.org/article/fetchObjectAt...

flosz 27 mei 2009 16:02

0

Vaxem....zonder quin.

May 26, 2009 17:30 CET
Novartis to enter Japan vaccines market through agreement for Haemophilus Influenzae Type B (Hib) vaccine
• Marketing and distribution agreement with Takeda Pharmaceuticals for Vaxem-Hib® is another step in Novartis global vaccines expansion strategy.
• Takeda will become the exclusive partner for Vaxem-Hib in Japan and pay Novartis 100 million Yen and milestone and royalty payments.
• Hib infection is responsible for an estimated 386,000 deaths per year worldwide.
Basel, May 26, 2009 - Novartis announced today that it has entered an agreement with the Takeda Pharmaceutical Company in Japan for the distribution of the Novartis Vaxem-Hib® vaccine for the prevention of infection caused by Haemophilus influenzae type B (Hib). Through this agreement, Novartis will manufacture the vaccine and supply it to Takeda, which will obtain exclusive rights to license, market and distribute the vaccine in Japan.
The WHO estimates that Hib is responsible for some three million serious illnesses and an estimated 386,000 deaths per year world wide, chiefly through meningitis and pneumonia[1]. Every year in Japan, 7.5 per 100,000, or more than 450 children, under the age of five are affected by Hib meningitis[2]. Almost all victims are children under the age of five[1].
"Novartis is committed to bringing Vaxem-Hib® to Japan as soon as possible to help protect Japanese children from Meningitis and other Hib induced infectious diseases through this strategic partnership with Takeda," said Dr. Andrin Oswald, CEO of Novartis Vaccines and Diagnostics. "Vaxem-Hib® is the first of many vaccines that Novartis hopes to bring to Japan to help improve public health and address unmet medical needs."
Vaxem-Hib® will mark Novartis entrance into the Japan vaccines market and is part of Novartis Vaccines global expansion strategy. Japan is the world's third largest vaccine market valued at USD 640 million and is expected to grow further.
With this agreement Takeda will become the exclusive partner for Vaxem-Hib in Japan, and will be responsible for conducting clinical trials and submitting a New Drug Application (NDA). Following approval, Takeda will label the product and sell the vaccine under the Novartis brand name. Under the terms of the deal, Takeda will pay Novartis 100 million Yen upfront and will be responsible for paying milestones and royalties in accordance with development and sales of the product.
www.novartis.com/newsroom/media-relea...

flosz 28 mei 2009 09:23

0

May 28, 2009 02:30 CET
Novartis increases its offer price on Novartis India Ltd.
This release is neither an offer to purchase nor a solicitation of an offer to sell shares of Novartis India Ltd.
Basel, Switzerland, May 28, 2009 - Novartis announced today an increase in the offer price for Novartis India Ltd. to Rs 450 per share, from Rs 351 initially proposed.
The revised offer represents a premium of 63% to the closing share price of Rs 275.6 of Novartis India Ltd. on March 24, which was the last trading day before announcement of the offer.
This proposal represents Novartis' only and final price revision to this offer, as May 28 is the last day on which the price can be revised.
www.novartis.com/newsroom/media-relea...

May 28, 2009 07:15 CET
Data on more than 15 Novartis Oncology compounds at ASCO highlight progress toward targeted therapies for diverse tumor types
www.novartis.com/newsroom/media-relea...

Novartis soars 20% as Swiss parent raises offer price
www.livemint.com/2009/05/28115848/Nov...

voda 29 mei 2009 15:12

0

Q-koorts in provincie Utrecht
29 mei 2009, 11:20 | ANP
UTRECHT (ANP) - In de provincie Utrecht zijn de eerste gevallen van de Q-koorts gesignaleerd. Negentien mensen uit het zuiden van de provincie zijn besmet met de infectieziekte, die wordt overgedragen van geiten en schapen op mensen. Dat maakte de GGD Midden-Nederland vrijdag bekend.

In Noord-Brabant en Gelderland zijn honderden patiënten met Q-koorts. Het is nog niet duidelijk of de ziekte is overgewaaid vanuit het zuiden of is ontstaan in Utrecht. In totaal zijn er dit jaar al 737 meldingen gedaan van besmetting.

Q-koorts wordt veroorzaakt door een bacterie en kan via de lucht worden verspreid. Klachten zijn hoge koorts, hoofdpijn en luchtwegklachten.

flosz 29 mei 2009 18:37

0

Registered Domains
wyethcrucell.com
Domain Name: wyethcrucell.com

Registrar: DIRECTI INTERNET SOLUTIONS PVT. LTD. D/B/A PUBLICDOMAINREGISTRY.COM
Whois Server: whois.PublicDomainRegistry.com
Referral URL: www.PublicDomainRegistry.com
Status: OK

Expiration Date: 2010-01-08
Creation Date: 2009-01-08
Last Update Date: 2009-03-10

Name Servers:
ns1.everydns.net
ns2.everydns.net
ns3.everydns.net
ns4.everydns.net
See wyethcrucell.com DNS Records

Information Updated: Fri, 29 May 2009 16:24:15 UTC

IP: 209.85.171.121
IP Location: Mountain View, United States

www.who.is/whois/wyethcrucell.com/

Biotech and pharmaceutical companies in Mountain View, Califonia

Caliper Life Sciences
Iconix Pharmaceuticals
InGenuity Systems

MedImmune

Pharsight
Vivus

www.thelabrat.com/jobs/companies/citi...

[verwijderd] 29 mei 2009 20:58

0

quote:
flosz schreef:
Registered Domains
wyethcrucell.com
Domain Name: wyethcrucell.com
...

Hier zit dus eeen vietnamees te hobbieen met domeinnamen:

www.who.is/whois/wyethcrucell.com/

Registrant:
N/A
Alex Tran (xxxxxxxxx@gmail.com)
216 Ly Thuong Kiet
Vinh Yen
Vinh Yen,84000
VN
Tel. +84.914510001

email 'm (of d'r?) eens, misschien weet ie/ze er meer van ;-)

M.i. inderdaad Geleuter in de marge :-)
Past hier dus beter dan in het officiele Wyeth draadje.

Mountain view heeft overigens inderdaad mooie uitzichten op de bergen, en daar zal ook vast de server voor dit domein zich bevinden.

flosz 29 mei 2009 21:15

0

quote:
maxen schreef:
mooie uitzichten

vietmodel.ning.com/profile/talextran

Btw. Wyethdraad ivm art. WSJ Dana….15 min. na post aossa:
Drug Bust: Where Are All the European Pharma Deals?
www.iex.nl/forum/topic.asp?forum=228&...

flosz 1 juni 2009 10:31

0

Cobra's oral vaccination platform
01 June 2009
Pharmaceutical Technology Europe interviews Dr Rocky Cranenburgh, Head of Molecular Biology at Cobra Biomanufacturing Plc, regarding the company's oral vaccine delivery technology.
…
Q5: What is currently hindering the widespread introduction of oral vaccines?
As with other drug delivery approaches, they have not translated well from animal to human applications. One reason for this is the metabolic burden on the bacteria, which reduces fitness and leads to plasmid loss. ORT-VAC addresses this critical issue. Another factor is the preparation of the bacteria such that they are lyophilized and encapsulated in a form that maintains viability, and ensures that they are released into the small intestine in an active form. We are working with the University of Cambridge (UK) on novel formulations to optimised oral delivery of live bacteria.
Conservatism in the pharmaceutical industry is also a factor, as needle-based vaccination is widespread and well understood. Persuading people to swallow Salmonella is another challenge, but Crucell’s typhoid vaccine 'Vivotif' is an attenuated (although not genetically modified) strain of Salmonella Typhi that is taken as a capsule, and has been safely used in humans for two decades. Further work also needs to be done to prevent survival in the environment, which is an area that we are currently working on.
www.ptemag.com/pharmtecheurope/Latest...

flosz 2 juni 2009 14:59

0

Reuters Summit-UPDATE 1-Vivalis to beat 2009 licensing goal
PARIS, June 2 (Reuters) - French biotechnology company Vivalis will beat its target of signing six to seven licensing deals this year and still expects to have more than 20 million euros in cash available at the end of 2009.
Chief Executive Franck Grimaud told Reuters at a biotech small- and mid-cap summit Vivalis would sign two licensing deals this quarter, one in vaccines and one in proteins. This will take the number in the first half to 7 and the total number of licensing agreements to 27.
Nantes-based Vivalis provides drugmakers and animal health companies with a technology based on duck egg cells that enables them to make preventative and therapeutic vaccines and proteins that can fight cancer. It is also developing its own drugs.
"With these two licenses, we will have fulfilled the goals we had set for this year, we will in fact surpass our objective," Grimaud said. Vivalis would reveal its new annual target later this year, he said.

Vivalis's key rival is Crucell .
www.guardian.co.uk/business/feedartic...

Voor Lucky Ducks…naar Whitby:
www.whitbyluckyducks.com/
(Nog leuker…..op het kerkhof(St Mary's) even langs het graf van Dracula.

flosz 3 juni 2009 09:33

1

Novartis Chief May Waive Chance to Buy Alcon After Share Slump
June 3 (Bloomberg) -- Novartis AG may pass on a chance to buy a majority stake in eye-care company Alcon Inc. for $28.2 billion after Alcon shares slumped, Chief Executive Officer Daniel Vasella said.
Novartis last year acquired 25 percent of Alcon from Nestle SA for $143.18 a share, or $11 billion. Under the agreement, Novartis can purchase another 52 percent between January 2010 and July 2011 for $181 a share. Alcon has fallen 25 percent since Nestle and Novartis announced the deal on April 7, 2008, closing yesterday on the New York Stock Exchange at $111.45.
Buying Alcon would help Basel, Switzerland-based Novartis reduce its reliance on pharmaceuticals at a time when its biggest-selling drugs, the hypertension treatment Diovan and the cancer drug Gleevec, are set to lose patent protection. Still, completing the purchase would require the drugmaker to pay a 62 percent premium over Alcon’s current price.
“You can calculate the likelihood of that happening,” Vasella, said in a May 28 interview in his Basel office. “From the point of the fundamentals, of the fit of the business, of the strategy, all that has not changed, but you cannot look at that in isolation. It is in a context of financial terms. I hope that it can be done, but obviously there are also significant uncertainties.”
Novartis may still end up buying the Alcon stake. Nestle can require Novartis to buy the shares at a 20.5 percent premium to Alcon’s stock price when the option is exercised, up to a maximum of $181. A Nestle spokeswoman declined to comment on whether it plans to exercise that option. The remaining 23 percent of Alcon, the world’s largest eye-care products company, is publicly traded.
Vasella, 55, also said that two personnel moves in the past seven months -- elevating Joerg Reinhardt to chief operating officer and hiring Jonathan Symonds as chief financial officer - - will give the board options in planning for Vasella’s successor.
In past years, Novartis reduced its dependence on prescription medicines by developing generic drugs and expanding its vaccine unit by acquiring Chiron Corp.

Vasella repeated that he’s looking for acquisitions to aid growth.
“If we can acquire now at a decent price then we should,” he said. Acquisitions “could be biotechs, could be generics could be vaccines. If we can make the case that it adds value more than cash, we would do it.”

Smaller Deals
Novartis, along with GlaxoSmithKline Plc and AstraZeneca Plc in the U.K. and France’s Sanofi, has said it prefers smaller deals to megamergers. This year, Pfizer Inc. agreed to acquire Wyeth for $63.6 billion, Merck & Co. said it will pay about $46 billion for Schering-Plough Corp. and Roche Holding AG purchased the rest of Genentech Inc. for $46.8 billion.

“The question is: why do you consider big transactions, and I think the worst reason is because it is fashion,” the Novartis chief executive said.

In October, Vasella shook up top management, replacing the heads of three of four business units. He moved Reinhardt from head of the vaccines unit into the new position of chief operating officer, sharing leadership duties with Vasella. Last month, the company hired Symonds, a former AstraZeneca executive-turned investment banker.
While Vasella declined to say how long he planned to stay in his job, he said succession played a role in both moves.

“Succession planning is not an option, it’s a must,” Vasella said. “You don’t want to be in front of a situation where you have one choice. One choice is no choice.”
www.bloomberg.com/apps/news?pid=20601...

Novartis successfully launches EUR 1.5 billion notes issue
Basel, Switzerland, June 2, 2009 - Novartis has successfully launched a notes issue of EUR 1.5 billion with a coupon of 4.25% under its EUR 15 billion Euro Medium Term Note Programme. Proceeds will be used for general corporate purposes.
The seven-year note was priced at 99.757% and has a maturity date of June 15, 2016. It is guaranteed by Novartis AG, which is incorporated in Switzerland and is the ultimate parent company of Novartis Finance S.A., Luxembourg, the issuing entity.
This offering was met with considerable interest, reflected by the fact it was oversubscribed more than four times and was placed to a diversified and international investor base.
www.novartis.com/newsroom/media-relea...

voda 3 juni 2009 20:41

2

Flosz, meer aandacht voor dit onderwerp:

VS willen cijfers van China over Tiananmenbloedbad
3 juni 2009, 20:20 | ANP
WASHINGTON (ANP) - De Verenigde Staten hebben China opgeroepen het aantal slachtoffers van de neergeslagen studentenprotesten op het Tiananmenplein in Peking van twintig jaar geleden openbaar te maken. De Chinese autoriteiten zouden de cijfers over doden, gevangenen en vermisten moeten vrijgeven.

Dat verklaarde de Amerikaanse minister van Buitenlandse Zaken, Hillary Clinton, aan de vooravond van de twintigste herdenking van de studentenopstand van 1989 voor meer democratie. Clinton riep China op de zwarte bladzijden uit zijn verleden openlijk te onderzoeken, ,,zowel om ervan te leren als om te helen''.

aossa 4 juni 2009 12:16

0

Veiling omschrijving

Online publieke veiling van productiemachines t.b.v. de pharmaceutische industrie in opdracht van 'Solvay Pharmaceuticals B.V.' wegens het beeindigen van de productie activiteiten te Weesp.

www.troostwijkauctions.com/nl/solvay-...

Aanvang veiling: 18/06/2009

Wie weet meer over de beeindiging van de productie activiteiten. Imo wordt in Weesp het flu vaccine gefabriceerd.

flosz 4 juni 2009 13:55

0

Nog wat restanten-opruiming imo ivm sluiting oude fabriek.

In het jaarverslag van 2007 vermelding opstartkosten ivm bouw nieuwe fabriek voor de productie van Influvac, op basis van cellencultuur (18 miljoen EUR).

Uit 2004, pag.3.
www.weesper.nl/weespernieuws/pdf/2004...

flosz 4 juni 2009 19:40

0

Novartis Vaccines Institute Gets Roughly $7M to Develop Bivalent Typhoid Vaccine

The Novartis Vaccines Institute for Global Health (NVGH) was awarded a €5.15 million grant by the U.K.’s Wellcome Trust biomedical charity for development of a bivalent typhoid vaccine.
The Wellcome Trust grant will fund preclinical development as well as Phase I and II trials. The organization will also provide expert advice, project support, and strategic oversight.
Based on a prototype conjugate vaccine developed by the NIH, the new NVGH vaccine will be designed to protect against both S. typhi and S. paratyphi A in adults as well as even in infants. Clinical trials are expected to start by the end of 2010.

There is currently no vaccine against S. paratyphi A, and available vaccines against S. typhi are not licensed for use in infants and young children. “The bivalent vaccine being developed by NVGH will use a novel approach to increase efficacy and address the needs of patients that other vaccines have not,” comments Daniel Vasella, Novartis chairman and CEO. “This will ultimately have the potential to eradicate this disease.”
Currently available typhoid vaccines include Typhim Vi® (Sanofi Pasteur) and Typherix® (GlaxoSmithKline), both injectable vaccines based on the S. typhi Vi polysaccharide. Vivotif® (Crucell/Berna Biotech) is an oral vaccine containing live-attenuated strain Ty21a.

_____________

June 04, 2009 07:15 CET
Novartis announces typhoid vaccine research program in partnership with the Wellcome Trust
• Novartis Vaccines Institute for Global Health (NVGH) developing bivalent vaccine to prevent Typhoid, which affects over 21 million people worldwide annually
• New grant from the Wellcome Trust funds progression of vaccine from preclinical through Phase I and II studies with view to protect against both S. Typhi and S. Paratyphi strains
• New vaccines an urgent priority as no vaccine available for S. Typhi for use in young children and infants and no vaccine available at all for S. Paratyphi A.
Basel, June 4, 2009 - Novartis announced that the Novartis Vaccines Institute for Global Health (NVGH) has been awarded a grant from the Wellcome Trust to develop a bivalent vaccine for Typhoid fever, a disease that affects more than 21 million people worldwide every year.
The Euro 5.15 million grant will fund preclinical development and Phase I and II studies for a vaccine that protects against both S. Typhi and S. Paratyphi A; two very similar illnesses which, if left untreated, can result in complications and death. The currently available vaccines for S. Typhi do not protect infants and young children. S. Paratyphi A is a growing problem causing 25-50% of all Typhoid cases.
"With more than 21 million cases of Typhoid fever worldwide and more than 600,000 deaths each year, this disease is a serious global health issue, especially in the developing world," said Dr. Daniel Vasella, Chairman and CEO of Novartis. "The bivalent vaccine being developed by NVGH will use a novel approach to increase efficacy and address the needs of patients that other vaccines have not. This will ultimately have the potential to eradicate this disease."
The NVGH opened in 2008 with a focus on addressing the unmet medical need for vaccines for diseases of the developing world. In addition to leveraging prior experience in R&D for the development of conjugate vaccines targeting Salmonella, NVGH research will build upon a promising prototype conjugate vaccine developed by the National Institutes of Health (NIH). NVGH aims to have a product ready for clinical trials by the end of 2010.
Expert advice, project support, and strategic oversight will be provided by the Wellcome Trust.
"This initiative is a welcome and important contribution to the fight against infection" said Dr. Ted Bianco, Director of Technology Transfer at the Wellcome Trust. "Partnerships between public and private sector research give us the best chance of effectively addressing the R&D needs of neglected diseases. The concept of developing a vaccine that can protect against both causative agents of Typhoid Fever makes great sense from a public health perspective, but requires a team of great skill to bring to fruition. I wish the NVGH team every success in this exciting endeavor."
www.novartis.com/newsroom/media-relea...

aossa 9 juni 2009 19:33

0

GSK and Shenzhen Neptunus create new alliance to develop and manufacture influenza vaccines in China

Issued: 9 June 2009, London UK

GlaxoSmithKline plc (GSK) today announced it has entered into a definitive agreement to form a new Joint Venture with Shenzhen Neptunus Interlong Bio-Technique Co. Ltd (Shenzhen Neptunus) focused on developing and manufacturing influenza vaccines for the Chinese market.

Jean Stéphenne, President and General Manager of GlaxoSmithKline Biologicals, said, "This new alliance enables GSK to build new vaccines capability in a critical emerging market such as China. The new Joint Venture will combine the potential of GSK's adjuvant technology and expertise in vaccine development together with the extensive experience of Shenzhen Neptunus in the Chinese vaccines market. Together we will gain access to specific local influenza antigens and make available new vaccines to benefit public health in China and neighbouring territories."

The alliance will develop and manufacture influenza vaccines for China, Hong Kong and Macau. This will include vaccines for seasonal, pre-pandemic and pandemic influenza. It is expected that these vaccines will become available over the next few years. The Joint Venture is expected to benefit from the differing expertise that both companies have in developing vaccines. Specifically, GSK will provide access to its proprietary adjuvant system which helps to improve efficiency and optimise production by increasing the number of vaccine doses that can be produced using a smaller amount of antigen. Shenzhen Neptunus will provide additional local manufacturing capacity and R&D expertise. Both companies will provide further investment in manufacturing.

GSK will take a 40% stake in the Joint Venture for a contribution of cash and assets equivalent to £21m. Shenzhen Neptunus will take a 60% stake in the Joint Venture for a contribution of cash and assets equivalent to £31m. Profits attributable to these assets are negligible.

Under the terms of the agreement, GSK is expected to purchase additional shares and obtain a majority equity interest in the Joint Venture within the next two years.

Completion of the transaction is expected in the fourth quarter of 2009, subject to local regulatory approval.

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com

www.gsk.com/media/pressreleases/2009/...

flosz 9 juni 2009 19:41

0

Eerder in 2008:
www.gsk.com/media/pressreleases/2008/...

flosz 10 juni 2009 09:17

0

Daiichi Sankyo Seeks Biotechnology, Cardiovascular Takeovers
Wednesday 10 June 2009
Daiichi Sankyo Co. is seeking biotechnology acquisitions in Europe to advance cancer research, and will use $5 billion in funds to enter new markets and fill gaps in its heart-drug portfolio.
Japan’s third-largest drugmaker, based in Tokyo, will need takeovers to reach its goal of 1 billion euros ($1.4 billion) sales in Europe in 2011, said Reinhard Bauer, the company’s head of European operations, in an interview today.
Daiichi Sankyo’s acquisition last year of about 600 sales people in Germany, Turkey and Ireland from Merck KGaA’s Merck Serono unit is an example of a type of deal that can help the Japanese company sell its products in markets in which it doesn’t have a sales force, Bauer said. Daiichi Sankyo aims to take share from Sanofi-Aventis SA’s Plavix with the Efient blood thinner it developed with Eli Lilly & Co. and introduced in Germany in April. Acquisitions will help it fill regional gaps in Eastern Europe and Scandinavia, he said.
With our existing portfolio and existing markets we can grow to a business volume on our own of 800 million euros, Bauer said. If we want to expand beyond that to the 1 billion- euro dimension, we would consider acquiring ourselves into new markets where we’re not yet present.
Daiichi Sankyo is researching biotechnology targets in Europe similar to German biotechnology company U3 Pharma AG, which it acquired last year, and is interested in new heart-drug candidates and cancer treatments, Bauer said. Daiichi Sankyo decided against an acquisition of Switzerland’s Nycomed A/S or Belgium’s Solvay SA.
Structural Needs
The transaction with Merck Serono satisfied our structural needs and this is something that Nycomed or Solvay could provide but we don’t need anymore, Bauer said. We have looked at the development projects and the pipeline of these companies, but they do not really have a synergy with our business focus of oncology or cardiology.
Efient, known chemically as prasugrel, is the first rival to Sanofi and Bristol-Myers Squibb Co.’s Plavix, the second- biggest selling drug in the world. Plavix generated $9.45 billion in 2008 and is approved for a broader group of patients. Only Pfizer Inc.’s cholesterol medicine Lipitor had more sales.
Analyst estimates of 1.5 billion euros ($2.1 million) in peak sales for Efient’s use with artery-opening stents is a fair assessment for the first indication. I believe we should be more ambitious, Bauer said.
Awaiting Decision
The two companies are waiting for a decision on the drug by the U.S. regulators. Prasugrel, twice delayed by the U.S. Food and Drug Administration, won a recommendation for approval on Feb. 3 by a panel of outside advisers to the FDA. Advisory panel decisions are typically adopted by the FDA.
Daiichi Sankyo bought U3 Pharma for 150 million euros in cash last year, gaining at least two potential cancer treatments.
U3, based in Martinsried near the southern city of Munich, was founded by Axel Ullrich, a professor of biochemistry whose research led to the development of Roche Holding AG’s Herceptin breast-cancer drug and Pfizer’s Sutent treatment for kidney tumors. Daiichi also has a partnership with Martinsried, Germany-based MorphoSys AG, which designs antibodies, or immune proteins, for drug development.
www.financial24.org/market/daiichi-sa...

AEX 924,10 -1,03 -0,11% 07 feb


Germany40^	21.738,40	-0,75%
BEL 20	4.337,66	+0,00%
Europe50^	5.319,41	-0,11%
US30^	44.342,20	0,00%
Nasd100^	21.508,40	0,00%
US500^	6.029,92	0,00%
Japan225^	38.404,40	0,00%
Gold spot	2.860,78	0,00%
EUR/USD	1,0327	0,00%
WTI	70,95	0,00%

THEON INTERNAT	+8,28%
AMG Critical ...	+3,34%
Aperam	+2,47%
UMG	+2,27%
AZERION	+1,83%

EBUSCO HOLDING	-4,60%
ALLFUNDS GROUP	-3,49%
TomTom	-2,57%
BESI	-2,41%
IMCD	-2,38%

Crucell « Terug naar discussie overzicht

Draadje OT, bijzaken & geleuter in de marge! - Deel 2

Meedoen aan de discussie?

Direct naar Forum

Markt vandaag

Aandelenadviezen van IEX.nl

Stijgers

Dalers